Physician profile
Mark E Mathieson
NPI 1144315821
$1,283.67
in general payments reported to CMS, 2019-2025
16 companies · $609 in 2025
The $609 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2022: $82.31 · 2023: $108 · 2024: $324 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $230.91 | 2019-2022 | |
| Pfizer INC. | $159.17 | 2024-2025 | |
| Strata Skin Sciences, INC. | $153.30 | 2025 | Xtrac |
| Sun Pharmaceutical Industries INC. | $142.78 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $140.63 | 2024 | Ycanth |
| Lnhc, INC | $121.36 | 2025 | Zelsuvmi |
| Mentor Worldwide LLC | $107.95 | 2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Regeneron Healthcare Solutions, INC. | $53.86 | 2024-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $38.29 | 2025 | Tremfya |
| Ucb, INC. | $30.47 | 2025 | Bimzelx |
| Biowound Solutions, INC. | $23.22 | 2025 | Bio-Connekt |
| Novartis Pharmaceuticals Corporation | $22.54 | 2025 | |
| Lilly USA, LLC | $19.85 | 2025 | Ebglyss, Taltz |
| Mimedx Group, INC. | $13.61 | 2024 | |
| Genzyme Corporation | $13.33 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mathieson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.